References
- Caplan A. Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax. 1953;8(1):29–37.
- Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol. 2008;18(2):109–118.
- Nakamura T. Amyloid A amyloidosis secondary to rheumatoid arthritis: development of pathophysiology and treatments. Clin Exp Rheumatol. 2011;29(5):850–857.
- Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018;70(10):1544–1554.
- Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358(9275):24–29.
- Steinbrocker O, Trager CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA. 1949;140(8):659–662.
- Nakamura T, Higashi S, Tomoda K, et al. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):43–49.
- Migita K, Agematsu K, Yazaki M, et al. Familial Mediterranean fever. Genotype-phenotype correlations in Japanese patients. Medicine (Baltimore). 2014;93(3):158–164.
- Ondrasik M. Caplan’s syndrome. Bailliere's. Clin Rheumatol. 1989;3(1):205–210.
- Mattson S-B. Caplan’s syndrome in association with asbestosis. Report of a case. Scand J Respir Dis. 1971;52(3):153–161.
- Schreiber J, Koschel D, Kekow J, et al. Rheumatoid pneumoconiosis (Caplan’s syndrome). Eur J Intern Med. 2010;21(3):168–172.
- Alaya Z, Braham M, Aissa S, et al. A case of Caplan syndrome in a recently diagnosed patient with silicosis: a case report. Radiol Case Rep. 2018;13(3):663–666.
- Capitani EMD, Schweller M, da Silva CM, et al. Rheumatoid pneumoconiosis (Caplan’s syndrome) with a classical presentation. J Bras Pneumol. 2009;35(9):942–946.
- Pernis B. Silica and the immune system. Acta Biomed. 2005;76(2):38–44.
- Migita K, Izumi Y, Jiuchi Y, et al. Serum amyloid A induces NLRP-3-mediated IL-1β secretion in neutrophils. PLoS One. 2014;9(5):e96703.
- Baba S, Masago SA, Takahashi T, et al. A novel allelic variant of serum amyloid A, SAAγ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet. 1995;4(6):1083–1087.
- Booth DR, Booth SE, Gillmore JD, et al. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid. 1998;5(4):262–265.
- Moriguchi M, Terai C, Kaneko H, et al. A novel single-nucleotide polymorphism at the 5’-flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis. Arthritis Rheum. 2001;44(6):1266–1272.
- Moriguchi M, Kaneko H, Terai C, et al. Relative transcriptional activities of SAA1 promoters polymorphic at position -13(T/C): potential association between increased transcription and amyloidosis. Amyloid. 2005;12(1):26–32.
- Utku U, Dilek M, Akpolat I, et al. SAA1 α/α alleles in Behçet’s disease related amyloidosis. Clin Rheumatol. 2007;26(6):927–929.
- Nakamura T, Migita K, Ando Y, et al. Amyloid A amyloidosis in a Japanese patient with familial Mediterranean fever associated with homozygosity for the pyrin variant M694I/M694I. Mod Rheumatol. 2014;24(2):349–352.
- Migita K, Agematsu K, Masumoto J, et al. The contribution of SAA1 polymorphisms to familial Mediterranean fever susceptibility in the Japanese population. PLoS One. 2013;8(2):e55227.
- Topaloglu R, Ozaltin F, Yimaz E, et al. E148Q is a disease-causing MEFV mutation: a phenotypic evaluation in patients with familial Mediterranean fever. Ann Rheum Dis. 2005;64(5):750–752.
- Saito D, Hibi N, Ozaki R, et al. MEFV gene-related enterocolitis account for some cases diagnosed as inflammatory bowel disease unclassified. Digestion. 2019;2019:1–9. doi: 10.1159/000502640
- Rabinovich E, Livneh A, Langevitz P, et al. Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene. Ann Rheum Dis. 2005;64(7):1009–1014.
- Okuda Y. AA amyloidosis-benefits and prospects of IL-6 inhibitors. Mod Rheumatol. 2019;29(2):268–274.
- Okuda Y, Yamada T, Ueda M, et al. First nationwide survey of 199 patients with amyloid A amyloidosis in Japan. Intern Med. 2018;57(23):3351–3355.
- Nakamura T, Shiraishi N, Morikami Y, et al. Systemic AA amyloidosis secondary to rheumatoid arthritis may be treatable but is still difficult to manage in daily clinical practice. Amyloid. 2019;26(1):123–124.